Pulse Biosciences to Report Third Quarter 2019 Operational Highlights and Financial Results
October 31 2019 - 1:51PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or
the “Company”), a novel bioelectric medicine company bringing to
market its proprietary CellFX™ System, announced today that the
Company will report third quarter 2019 operational updates and
highlights, along with financial results for third quarter on
Thursday, November 7, 2019. Pulse Biosciences management will host
a conference call at 4:30 p.m. Eastern Time (ET) / 1:30 p.m.
Pacific Time (PT).
Analysts and investors can participate in the conference call by
dialing (844) 494-0190 (domestic) and (508) 637-5580
(international) using the conference ID# 7381116. The conference
call can also be accessed live on the Investors section of the
Pulse Biosciences website at www.PulseBiosciences.com.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that improves and potentially
extends the lives of patients. The CellFX System is the first
planned commercial product to harness the distinctive advantages of
the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology
to treat a variety of applications for which an optimal solution
remains unfulfilled. NPS technology delivers nano-second pulses of
high amplitude electrical energy to non-thermally clear cells while
sparing adjacent non-cellular tissue. The cell-specific effects of
NPS technology have been validated in a series of ongoing clinical
trials. The CellFX System is preparing to launch in 2019 as a
multi-application platform designed to address a broad range of
dermatologic conditions. As part of the customer experience, the
Company is offering a utilization-based revenue model and
easy-access customer portal offering a suite of services. CellFX
procedures offer customer value across an expanding spectrum of
clinical applications. The initial commercial use will be in the
clearance of common and difficult to treat skin lesions that share
high demand among patients and practitioners for improved and
durable aesthetic outcomes that lead to greater overall
satisfaction.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse
Stimulation technology are for investigational use only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191031005812/en/
Investor Relations: Pulse Biosciences, Inc. Brian Dow Sr.
Vice President and Chief Financial Officer
IR@PulseBiosciences.com
Solebury Trout Gitanjali Jain Ogawa, 646-378-2949
gogawa@troutgroup.com
Media: Tosk Communications Nadine D. Tosk, 504-453-8344
nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Apr 2024 to May 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From May 2023 to May 2024